Uzbekistan is set to begin a phase-3 trial of coronavirus vaccine developed by China’s Anhui Zhifei Longcom Biopharmaceutical.
The vaccine will be tested on 5,000 volunteers. This was announced by Alisher Abdullayev, Deputy Director of the Center for Advanced Technologies under the Ministry of Innovation of Uzbekistan. According to him, the Chinese vaccine has already been transported to Tashkent and is stored under special conditions.
Abdullayev said that that 5,000 men and women aged between 18 and 59 will attend the third phase of the test process. For this, groups of volunteers are organized in each polyclinic in Tashkent.
Volunteers must be free from serious or chronic illnesses, allergies, or a history of COVID-19 or coronavirus infection prior to testing. The press will announce the launch of the selection of volunteers, after which they will undergo a medical examination.
In addition, at the end of the phase-3 trial, test volunteers will be entitled to payment. Also, all test candidates will be covered by insurance, that is, they will receive medical insurance.
Abdullayev said that during the tests in Uzbekistan, strict monitoring will be carried out, and in case of any side effects following the vaccine administration, trail would be suspended until the situation is clarified.
Earlier, Minister of Innovative Development Ibrohim Abdurahmanov said in an interview with the media that Uzbekistan is also planning to test in Uzbekistan vaccines manufactured in China, Russia, Europe and the United States.